Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW OKs IFN-Free Hepatitis C Treatments
July 8, 2014
- Keiya Iida of METI to Be First “Councilor for the Promotion of Pharmaceutical and Related Industries”: MHLW
July 8, 2014
- Kiyohito Nakai to Be Appointed Pharmaceutical Management Director
July 8, 2014
- Ryukaikon Council Member Requests Rewards instead of Penalties for Early Delivery Price Settlements
July 7, 2014
- Initiatives for Drug Distribution Improvement Advanced in FY2013: Ryukaikon Council
July 7, 2014
- Yuji Kanda to Head PFSB, Kazuo Futagawa to Head HPB Following Reshuffling of MHLW Top Officials
July 7, 2014
- MHLW to Issue Business Practice Improvement Order to Novartis for Violation of ADR Reporting Requirement
July 4, 2014
- MHLW to Require RMP Submissions around August for Generics of Blue Letter-Issued Original Drugs
July 2, 2014
- Ex-Novartis Employee, Japan Unit Indicted over Diovan Data Manipulation
July 1, 2014
- Govt Tax Panel Proposes Maintenance of Scaled-Down R&D Tax Credits
June 30, 2014
- JPMA Official Calls for Partial Introduction of CDISC-Based Electronic Applications; Runup Period too Short
June 30, 2014
- Benefits of Electronic Applications to Be Shared by Patients, Companies, and Regulatory Authorities: MHLW Exec
June 30, 2014
- PAFSC’s Second Committee Supports Approval of IFN-Free Hepatitis C Treatments
June 30, 2014
- Chuikyo to Resume Discussions on Diovan Ads’ Impact on Healthcare Finances
June 27, 2014
- MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
June 27, 2014
- Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
- Govt Approves Economic Strategies, Chuikyo Likely to Discuss NHI Price Revision Frequency
June 25, 2014
- Ryukaikon to Meet on July 2; FY2013 Price Settlement Rates to Be Reported
June 25, 2014
- MHLW Issues Notification on Electronic Applications
June 24, 2014
- Blopress Excluded from Generic Share Calculation until September
June 23, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…